Press release
Next Generation Immunotherapies Market Size Expected to Witness Significant Growth by 2034, estimates DelveInsight
DelveInsight's "Next Generation Immunotherapies Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of Next Generation Immunotherapies, historical and forecasted epidemiology, as well as the Next Generation Immunotherapies market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
Discover Key Insights into the Next Generation Immunotherapies Market with DelveInsight's In-Depth Report @ Next Generation Immunotherapies Market Size [https://www.delveinsight.com/report-store/next-generation-immunotherapies-market?utm_source=abnewswire&utm_medium=pr&utm_campaign=kkpr]
Key Takeaways from the Next Generation Immunotherapies Market Report
*
The leading Next Generation Immunotherapies companies include Bristol-Myers Squibb, Regeneron, Novartis, GlaxoSmithKline, Merck, Roche, AstraZeneca, and others.
*
Rising prevalence of cancer and autoimmune diseases globally is accelerating demand for advanced immunotherapies offering durable and targeted treatment outcomes.
*
Breakthroughs in CAR-T, TCR therapies, bispecific antibodies, and immune checkpoint modulators are expanding therapeutic applications and improving clinical efficacy.
*
The Next Generation Immunotherapies market in the 7MM is expected to witness major change during the study period 2020-2034.
*
Key targets currently under development include LAG-3, TIGIT, NKG2A, CD73, TIM-3, B7-H3, A2A receptor, FAK, CD47-SIRP receptor, and CSF-1, among others.
Stay ahead in the Next Generation Immunotherapies Market with DelveInsight's Strategic Report @ Next Generation Immunotherapies Market Outlook [https://www.delveinsight.com/report-store/next-generation-immunotherapies-market?utm_source=abnewswire&utm_medium=pr&utm_campaign=kkpr]
Next Generation Immunotherapies Epidemiology Segmentation in the 7MM
*
Total Next Generation Immunotherapies Market Size
*
Market Size by Therapies
*
Market Size by Class
*
Next Generation Immunotherapies Treatment Market
Next Generation Immunotherapies Pipeline Analysis
*
OPDUALAG (relatlimab/nivolumab): Bristol-Myers Squibb OPDUALAG is a first-in-class, fixed-dose combination of nivolumab and relatlimab, administered as a single intravenous infusion. It is the first LAG-3 inhibitor granted FDA approval in March 2022 for the treatment of adult and pediatric patients aged 12 years or older with unresectable or metastatic melanoma.
*
Fianlimab (REGN-3767): Regeneron Pharmaceuticals Fianlimab is a fully human monoclonal antibody targeting the immune checkpoint receptor LAG-3 on T cells. In melanoma, LAG-3 expression on cancer cells is associated with therapeutic resistance to PD-1 inhibitors. It is being investigated in combination with Regeneron's PD-1 inhibitor Libtayo to determine whether concurrent blockade of LAG-3 and PD-1 can help overcome resistance and enhance T-cell activation.
*
Cobolimab (GSK-4069889): GlaxoSmithKline Cobolimab is a monoclonal antibody targeting the inhibitory T-cell receptor TIM-3 (T-cell immunoglobulin and mucin domain-containing protein 3), with potential immune checkpoint inhibitory and antineoplastic activities.
*
Tiragolumab (RG-6058): Roche Tiragolumab is a novel immune checkpoint inhibitor with an intact Fc region that selectively binds to TIGIT, a novel inhibitory immune checkpoint that suppresses the immune response to cancer.
*
Ezabenlimab (BI-754091): Boehringer Ingelheim Ezabenlimab is a monoclonal antibody antagonist of the key myeloid cell checkpoint inhibitor SIRP, preventing the SIRP ligand CD47 from binding to SIRP and thereby preserving the anti-tumorigenic properties of myeloid cells such as macrophages and dendritic cells.
Next Generation Immunotherapies Market Insights
*
The current treatment landscape includes checkpoint inhibitors, monoclonal antibody inhibitors, immune system modulators, vaccines, virus therapies, adoptive cell transfer, T-cell therapy, and targeted therapies.
*
Cancer immunotherapy is now considered the "fifth pillar" of cancer therapy, joining surgery, cytotoxic chemotherapy, radiation, and targeted therapy.
*
The competitive landscape is highly dynamic and innovation-driven, with leading players advancing CAR-T and CAR-NK cell therapies, bispecific and multispecific antibodies, immune checkpoint inhibitors, and cancer vaccines.
*
Strategic collaborations, licensing agreements, and mergers are common as companies seek to strengthen pipelines and access novel platforms.
*
The expected introduction of emerging therapies with improved efficacy, greater awareness initiatives, and further improvement in diagnosis rates are likely to boost market growth across the 7MM.
Get In-Depth Knowledge on Next Generation Immunotherapies Market Trends and Forecasts with DelveInsight @ https://www.delveinsight.com/report-store/next-generation-immunotherapies-market [https://www.delveinsight.com/report-store/next-generation-immunotherapies-market?utm_source=abnewswire&utm_medium=pr&utm_campaign=kkpr]
Next Generation Immunotherapies Market Outlook
Cancer immunotherapy harnesses the patient's own immune system to fight cancer, distinguishing it from conventional therapies that directly target tumor cells. Immune checkpoints are pathways with inhibitory or stimulatory features that maintain self-tolerance and assist with immune response. Well-described checkpoints include CTLA-4, PD-1, and PD-L1. The Next Generation Immunotherapies pipeline is very robust, with many potential therapies under investigation, and the treatment space is expected to experience a significant market impact during the forecast period. Market growth may be offset by therapy failures or discontinuations, unaffordable pricing, market access and reimbursement issues, and a scarcity of healthcare specialists.
Scope of the Next Generation Immunotherapies Market Report
*
Coverage: 7MM
*
Study Period: 2020-2034
*
Forecast Period: 2024-2034
*
Next Generation Immunotherapies Companies: Bristol-Myers Squibb, Regeneron, GlaxoSmithKline, Roche, Boehringer Ingelheim, and others
*
Next Generation Immunotherapies Therapies: OPDUALAG, Fianlimab, Cobolimab, Tiragolumab, Ezabenlimab, and others
*
Next Generation Immunotherapies Market Access & Reimbursements, Unmet Needs and Perspectives
*
Next Generation Immunotherapies SWOT Analysis and KOL Views
Unlock Strategic Insights with DelveInsight's Comprehensive Next Generation Immunotherapies Market Report @ Next Generation Immunotherapies Market Drivers and Barriers [https://www.delveinsight.com/report-store/next-generation-immunotherapies-market?utm_source=abnewswire&utm_medium=pr&utm_campaign=kkpr]
Table of Contents
1. Key Insights
2. Report Introduction
3. NGIs Market Overview at a Glance
3.1. Market Share (%) Distribution of NGIs in 2020: By Country
3.2. Market Share (%) Distribution of NGIs in 2034: By Country
3.3. Market Share (%) Distribution of NGIs in 2025: By Indication
3.4. Market Share (%) Distribution of NGIs in 2034: By Indication
4. Key Highlights from Report
5. Executive Summary of NGIs
5.1. Key Events
6. Epidemiology and Market Forecast Flow
7. Background and Overview
7.1. Introduction
7.2. Different types of NGIs
7.3. Applications of NGIs
7.4. Mechanisms of Action of NGIs for Cancer Therapy
7.5. Routes of Administration
7.5.1. Direct intratumoral delivery
7.5.2. IV delivery
7.5.3. Other routes of delivery
7.5.4. Comparing different administration routes
8. Epidemiology and Patient Population
8.1. Key Findings
8.2. Assumptions and Rationale
8.3. Epidemiology Scenario in the 7MM
8.3.1. Total Incident cases of target indications across the 7MM
8.3.2. Target Patient Pool of NGIs across the 7MM
8.3.3. Treated cases by line of therapy across the 7MM
8.4. Epidemiology Scenario in the US
8.4.1. Total Incident cases of target indications across the US
8.4.2. Target Patient Pool of NGIs across the US
8.4.3. Treated cases by line of therapy across the US
8.5. Epidemiology Scenario in EU5
8.5.1. Total Incident cases of target indications across EU5
8.5.2. Target Patient Pool of NGIs across EU5
8.5.3. Treated cases by line of therapy across EU5
8.6. Epidemiology Scenario in Japan
8.6.1. Total Incident cases of target indications across Japan
8.6.2. Indication wise target patient pool across Japan
8.6.3. Treated cases by line of therapy across Japan
9. Key Endpoints in NGIs
10. Marketed therapies
10.1. Key Cross of Marketed Therapies
10.2. OPDUALAG: Bristol Myers Squibb
10.2.1. Product description
10.2.2. Regulatory milestones
10.2.3. Other developmental activities
10.2.4. Pivotal clinical trial
10.2.5. Ongoing pipeline activity
11. Emerging Therapies
11.1. Key Cross Competition
11.2. Fianlimab (REGN-3767) : Regeneron Pharmaceuticals
11.2.1. Product description
11.2.2. Other developmental activities
11.2.3. Clinical development
11.2.4. Safety and efficacy
11.3. Tebotelimab (MGD013) : MacroGenics
11.3.1. Product description
11.3.2. Other developmental activities
11.3.3. Clinical development
11.3.4. Safety and efficacy
11.4. Ezabenlimab (BI-754091): Boehringer Ingelheim
11.4.1. Product description
11.4.2. Other developmental activities
11.4.3. Clinical development
11.4.4. Safety and efficacy
11.5. MGC 018 : MacroGenics
11.5.1. Product description
11.5.2. Other Developmental Activities
11.5.3. Clinical development
11.5.4. Safety and efficacy
11.6. Etigilimab : MereoBiopharma
11.6.1. Product description
11.6.2. Other developmental activities
11.6.3. Clinical development
11.6.4. Safety and efficacy
11.7. HB-0036 : Hubao Biopharm
11.7.1. Product description
11.7.2. Other developmental activities
11.7.3. Clinical development
11.7.4. Safety and efficacy
To be continued in the report...
12. Attribute Analysis
13. Next Generation Immunotherapies: 7 Major Market Analysis
13.1. Key Findings
13.2. Market Outlook
13.3. Market Size of NGIs in the 7MM
13.3.1. Total Market Size of NGIs
13.3.2. Total Market Size of NGIs by Indications in the 7MM
13.3.3. Market Size of NGIs by Therapies
13.4. Market Size of NGIs in the US
13.4.1. Total Market Size of NGIs
13.4.2. Total Market Size of NGIs by Indications
13.4.3. Market Size of NGIs by Therapies in the US
13.5. Market Size of NGIs in EU5
13.5.1. Total Market Size of NGIs
13.5.2. Total Market Size of NGIs by Indications
13.5.3. Market Size of NGIs by Therapies in EU5
13.6. Market Size of NGIs in Japan
13.6.1. Total Market Size of NGIs
13.6.2. Total Market Size of NGIs by Indications
13.6.3. Market Size of NGIs by Therapies in Japan
14. Market Access and Reimbursement
14.1. NICE UK
14.2. IQWiG and GBA Assessment
14.3. Japan
14.4. Patient assistance programs
15. KOL Views
16. SWOT Analysis
17. Unmet Needs
18. Appendix
18.1. Acronyms and Abbreviations
18.2. Bibliography
18.3. Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
Related Reports
LAG-3 Next-generation Immunotherapy- Competitive Landscape and Market Forecast-2035 [https://www.delveinsight.com/report-store/lag-3-next-generation-immunotherapy-competitive-landscape?utm_source=abnewswire&utm_medium=pr&utm_campaign=kkpr]
DelveInsight's "Lymphocyte Activation Gene-3 (LAG-3) Competitive Landscape and Market Forecast - 2035" report delivers an in-depth understanding of the LAG-3, historical and forecasted market trends of LAG-3 in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.Key LAG-3 Next-generation Immunotherapy companies working in the LAG-3 Next-generation Immunotherapy market are Bristol-Myers Squibb, Merck Sharp & Dohme Corp., MacroGenics, Immutep, Incyte Corporation, F-star Therapeutics, EpimAb Biotherapeutics, Roche, Xencor, AnaptysBio, GlaxoSmithKline, Regeneron Pharmaceuticals, Sanofi, Symphogen, and others.
ICOS-Next Generation Immunotherapy - Competitive Landscape and Market Forecast - 2035 [https://www.delveinsight.com/report-store/icos-next-generation-immunotherapy-competitive-landscape?utm_source=abnewswire&utm_medium=pr&utm_campaign=kkpr]
DelveInsight's 'ICOS-Next Generation Immunotherapy Competitive Landscape and Market Forecast-2035' report delivers an in-depth understanding of the ICOS as well as the ICOS-Next Generation Immunotherapy therapeutics market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kanishk Kumar
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=next-generation-immunotherapies-market-size-expected-to-witness-significant-growth-by-2034-estimates-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/next-generation-immunotherapies-market
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Next Generation Immunotherapies Market Size Expected to Witness Significant Growth by 2034, estimates DelveInsight here
News-ID: 4539056 • Views: …
More Releases from ABNewswire
Cytokine Release Syndrome Market Emerging as a High-Growth Healthcare Investment …
The Key Cytokine Release Syndrome Companies in the market include - Genentech, Swedish Orphan Biovitrum (sobi), Incyte, Kite, A Gilead Company, Jazz Pharmaceuticals, Fred Hutchinson Cancer Center, Ontario Clinical Oncology Group, GlaxoSmithKline, UNC Lineberger Comprehensive Cancer Center, SCRI Development Innovations and others.
The Cytokine Release Syndrome market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Cytokine Release Syndrome pipeline…
Dry Age-Related Macular Degeneration Market is Projected to Grow at ~19.2% CAGR …
Key companies like Astellas Pharma/Iveric Bio, Apellis Pharmaceuticals, Belite Bio, Alkeus Pharmaceuticals, Aviceda Therapeutics, Allegro Ophthalmics, Johnson & Johnson Innovative Medicine, and others are leading the exponential growth in the market.
DelveInsight's "Dry Age-Related Macular Degeneration Market Insight, Epidemiology and Market Forecast - 2036" report delivers an in-depth understanding of Dry Age-Related Macular Degeneration (AMD), historical and forecasted epidemiology as well as the Dry AMD market trends in the United States,…
Fuchs Endothelial Corneal Dystrophy Market Shows Strong Growth Potential with Em …
DelveInsight's "Fuchs Endothelial Corneal Dystrophy Market Insights, Epidemiology, and Market Forecast-2036" report offers an in-depth understanding of Fuchs Endothelial Corneal Dystrophy, historical and forecasted epidemiology as well as the FECD market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
The Key Fuchs Endothelial Corneal Dystrophy Companies in the market include - Kowa Pharmaceuticals, Trefoil Therapeutics, Santen, ActualEyes, Alcon, Emmecell, AJL Ophthalmic SA, Massachusetts Eye…
CAR-T Pipeline Expands as 180+ Companies Driving Innovation in the Therapeutics …
DelveInsight's "CAR T-Cell Therapy Pipeline Insight 2026" report provides comprehensive insights about 180+ companies and 200+ pipeline drugs in the CAR T-Cell Therapy pipeline landscape. It covers the CAR T-Cell Therapy Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the CAR T-Cell Therapy Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Curious…
More Releases for Generation
Digital Services for Lead Generation | Local Lead Generation Websites | Lead Gen …
Lead Generation consists of attracting and renovating target audiences that have shown interest in your product or services. The objective is to guide prospects through the purchaser’s journey to the end of the sales funnel. Content is one of the leading tools B2B marketers utilize to create leads. This may comprise of social media posts, blog posts, coupons and live events. You utilize the forms to capture leads that employ…
Digital Services for Lead Generation, Local Lead Generation Websites
Businesses these days are reliant on lead generation to advertise their service before the consumers to get more business and endure in bullish market. The Lead generation service is an unceasing effort to attract and change the target audience’s mind towards the business offering. It is an act of completely compelling the consumer to purchase the business services. It will boost brand image and outcome in good sales for the…
Digital Services for Lead Generation, Lead Generation Platforms: Ken Research
The Lead generation is the practice of gaining fresh leads for your business. It is cultivating the interest of a person in your product or service so much that they distribute you with their contact specifics. It is the start of the technique which leads to a prospective customer turning into a purchaser. And then perchance buying from your business. Your business should then be nurturing such leads that you…
Digital Services for Lead Generation | Lead Generation Platforms: Ken Research
There are several channels and marketing tools for the digital marketers to utilize to get customers to notice their brand. If your business functions appropriate when in direct communication with the customers over the phone, the lead generation marketing can provide a number of benefits.
The lead generation marketing is about motivating the interest of customers in a product or service and capturing that interest by obtaining those customers to…
Local Lead Generation Websites | Best Companies for Online Lead Generation | Lea …
The Lead Generation is a foremost marketing procedure that comprise finding people who would be interested in purchasing your product and/or services. It comprises collecting contact details of the interested impending buyers/consumers in exchange for something that is of worth to them - for e.g educational, collateral, research content or a free trial of a product. This is a foremost activity to build a sales pipeline. The Lead Generation is…
lead generation company | Best Lead Generation Company in India | Online Lead Ge …
Lead Generation: The Lead generation firms supply your corporate with the hot leads you necessary to acquire fresh clients, while releasing up your time to spend on other responsibilities, like product improvement or quality declaration. Contrariwise, you could double down on fresh leads, hammering up business in tandem with leads delivered by the generation firms. The Business enlargement is openly correlated with finding fresh clients and making them happy, and…
